Scarica l'app Stockscreener
109.33
0.39%
0.42
Dopo l'orario di chiusura:
109.54
0.21
+0.19%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Morgan Stanley Reaffirms Overweight on Gilead Sciences, Inc. (GILD), Citing LEN Potential - Insider Monkey
Morgan Stanley reiterates overweight rating on Gilead Sciences stock - Investing.com
Morgan Stanley reiterates overweight rating on Gilead Sciences stock By Investing.com - Investing.com UK
Gilead Sciences Insider Sold Shares Worth $1,104,193, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
Citi Analysts Affirm Buy Rating on Gilead Sciences (GILD) Stock - Insider Monkey
Beyond Blood Cancers: New Explorations in CAR T-cell Therapy - Gilead Sciences
Gilead Sciences Commemorated the Opening of the Bay Area Young Survivors Breast Cancer Memorial Garden - CSRwire
Gilead Reports Positive Data From Trodelvy, Keytruda Combo Study - Zacks Investment Research
Gilead Sciences a Top Socially Responsible Dividend Stock With 2.9% Yield (GILD) - Nasdaq
Merck, Gilead Combination Reduces Disease-Progression Risk of Breast Cancer in Phase 3 Study - marketscreener.com
Citi analysts reaffirm Gilead Sciences stock Buy rating for Trodelvy data - Investing.com
Gilead’s Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial By Reuters - Investing.com
Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial - Reuters
Gilead Sciences, Inc. (GILD)’s Breast Cancer Study Success Drives Investor Optimism Amid Broader Market Slump - MSN
Gilead (GILD) Presents Yescarta Study Results at ASCO 2025 | GILD Stock News - GuruFocus
GILD: Gilead's Trodelvy Shows Significant Benefit in Breast Canc - GuruFocus
GILD: Gilead's Trodelvy Shows Significant Benefit in Breast Cancer Study | GILD Stock News - GuruFocus
ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC - pharmaphorum
The Academy of Oncology Nurse & Patient Navigators and Gilead Sciences Partner to Launch Oncology Navigation Grant Program - PR Newswire
Gilead's CAR-T cell therapy shows promise in deadly brain cancer - Reuters
Gilead Sciences, Inc, (GILD)’s Trodelvy and Merck & Co., Inc, (MRK)’s Keytruda Cuts Breast Cancer Progression Risk by 35% - Insider Monkey
Gilead Sciences (GILD) Reports Positive Results for Trodelvy Com - GuruFocus
Gilead’s Trodelvy with Merck’s Keytruda cuts disease progression/ death in breast cancer - Seeking Alpha
Transforming How Cancer Is Treated: Research Results To Be Shared at ASCO25 - CSRwire
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold? - The Globe and Mail
Gilead Sciences Commemorated the Opening of the Bay Area Young S - GuruFocus
Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance By Stocktwits - Investing.com India
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty - Reuters
Gilead Sciences Plans to Supply Twice-Yearly HIV Prevention Shot to Low-Income Countries Pending FDA Approval - geneonline.com
Gilead at Bernstein Conference: Strategic Growth and Innovation - Investing.com
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Gilead at Bernstein Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK
Transcript : Gilead Sciences, Inc. Presents at Bernstein 41st Annual Strategic Decisions Conference 2025, May-29-2025 02 - marketscreener.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock - Yahoo Finance
Gilead Sciences and Kite Pharma To Announce Transformative - CSRwire
Gilead Sciences’ SWOT analysis: HIV giant faces oncology growth, patent cliff - Investing.com Nigeria
ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs - insights.citeline.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Gilead Sciences' Best Days May Be AheadHere's Why (NASDAQ:GILD) - Seeking Alpha
GILD Announces Positive Data on Trodelvy in First-Line Breast Cancer - Yahoo Finance
Gilead’s Phase III trial for breast cancer therapy meets primary goal - Clinical Trials Arena
Gilead says Trodelvy ASCENT-03 study meets primary endpoint - The Pharma Letter
Gilead announces ASCENT-03 study meets primary endpoint - Yahoo Finance
0.47%
0.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):